

PTX-100 investor update and additional patient response

MELBOURNE Australia, 2 November 2022: Prescient Therapeutics (ASX: PTX), a clinical stage oncology company developing personalised therapies to treat cancer, will be holding an investor briefing on Wednesday 2nd November at 12pm (AEDT).

CEO and Managing Director Steven Yatomi-Clarke will provide a company update, outlining Prescient's cutting-edge pipeline and an update from the PTX-100 Phase 1b expansion cohort study.

Since Prescient's recent PTX-100 trial update on 25 October 2022, there has been an additional reported clinical response, with a patient with relapsed peripheral T cell lymphoma (PTCL) reporting a partial response. The increasing clinical responses observed in this study provides growing confidence in the potential for PTX-100 in this area of poorly met medical need.

To register for the investor briefing, visit this page:

<https://prescienttherapeutics.investorportal.com.au/investor-briefing/>

A copy of the investor presentation to be presented is attached.

- Ends -

To stay updated with the latest company news and announcements, [please update your details](#) on our investor centre.

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Cell Therapies

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post- translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets.



The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Prescient is developing OmniCAR programs for next-generation CAR-T therapies for Acute Myeloid Leukemia (AML); Her2+ solid tumours, including breast, ovarian and gastric cancers; and glioblastoma multiforme (GBM).

CellPryme-M: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

CellPryme-A: CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pre-treated CAR-T cells.

Targeted Therapies

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX-100 is believed to be the only GGT-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 is now in a Phase 1b expansion cohort study in T cell lymphomas, where it has shown encouraging efficacy signals and safety.

PTX-200 is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition, PTX-200 has a novel mechanism of action that specifically inhibits Akt without non-specific kinase inhibition effects. This highly promising compound is currently in a Phase 1b/2 trial in relapsed and refractory AML, where it has resulted in 4 complete remissions so far. PTX-200 previously generated encouraging Phase 2a data in HER2-negative breast cancer and Phase 1b in recurrent or persistent platinum resistant ovarian cancer.

Find out more at www.ptxtherapeutics.com or connect with us via Twitter [@PTX_AUS](https://twitter.com/PTX_AUS) and [LinkedIn](https://www.linkedin.com/company/ptxtherapeutics).

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

For more information please contact:

Company enquiries

Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics
steven@ptxtherapeutics.com

Investor enquiries

Sophie Bradley
Reach Markets
+61 450 423 331
ir@reachmarkets.com.au

Media enquiries

Andrew Geddes
CityPR
+61 2 9267 4511
ageddes@citypublicrelations.com.au

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

Supplemental COVID-19 Risk Factors

Please see our website: [Supplemental COVID-19 Risk Factors](#)

Internal use only



Prescient
Therapeutics

IN FRONT OF THE BIGGEST WAVE IN ONCOLOGY

November 2022

Disclaimer and safe harbor



Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this presentation. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

The contents of this document are confidential information of Prescient. These contents are made available on a 'for your eyes only' basis to the person to whom it was sent by Prescient. The purpose of the disclosure is to facilitate commercial and confidential discussions between the discloser and Prescient. It should not be forwarded without the prior written consent of the Company.

This is not an offer of securities in any place outside Australia or New Zealand and does not take into account your individual investment objectives, financial situation or particular needs. An investment in the Company is speculative. Therefore, you should obtain independent financial and taxation advice before making an investment decision. Before making an investment decision, you should read the SPP terms in the Offer Booklet.

Corporate snapshot

| | |
|-------------------|------------|
| ASX Ticker | PTX |
|-------------------|------------|

| | |
|----------------------|--------------|
| Total Issued Capital | 705 M shares |
|----------------------|--------------|

| | |
|----------------|--------|
| Listed Options | 85.4 M |
|----------------|--------|

| | |
|------------------|--------|
| Unlisted Options | 38.3 M |
|------------------|--------|

| | |
|--------------------------|---------|
| Share Price ¹ | A\$0.17 |
|--------------------------|---------|

| | |
|--|-----------------|
| Market Capitalisation¹ | A\$120 M |
|--|-----------------|

| | |
|---|-----------------|
| Market Cap fully diluted¹ | A\$140 M |
|---|-----------------|

| | |
|----------------------------------|---------------|
| Cash Position² | A\$21M |
|----------------------------------|---------------|

| | |
|------------|-----|
| Top 20 Own | 16% |
|------------|-----|



1 - AS AT 24 OCT 2022

2 - UNAUDITED, POST OCT 2022 CAPITAL RAISING

Investment Highlights



World class pedigree.

We license from the best;
and work with the best



THE UNIVERSITY OF TEXAS



Many shots on goal for
substantial value creation



2 Cell Therapy platforms

Internal & external opportunities



2 Targeted Therapies


in clinical trials, showing activity



Upcoming newsflow

from multiple programs

Very productive Sept quarter



4 Innovative Personalised Oncology Assets

Cell therapy platforms



OmniCAR



CellPryme-M



CellPryme-A

Next-gen CAR-T therapies

CD33/CLL-1

Acute Myeloid
Leukaemia

Her2/EGFRviii

Glioblastoma
Multiforme

Her2

Breast, Ovarian &
Gastric cancers

Targeted therapies


PTX-100

Ras / Rho
inhibitor


PTX-200

Novel AKT
inhibition

Innovative pipeline in personalised medicine



analysis only



TARGETED THERAPIES

ial use only

PTX-100

FIRST IN CLASS
RAS PATHWAY INHIBITOR

PTX-100 Phase 1B Summary

- Licensed from Yale University
- Targeting cancers predisposed to Ras & Rho mutations

Phase 1b Expansion cohort in T-cell lymphomas (TCL)

- Excellent safety profile
- Encouraging signal in TCL
 - Responses
 - Time on therapy

- Granted Orphan Drug Designation by US FDA for Peripheral TCL



Licensed from



Yale University

Principal Investigator




Professor H. Miles Prince, AM



Epworth

Trial update: continued encouraging responses & time on treatment

CLINICAL REPOSSES & MONTHS ON TREATMENT



- ★ Very Good Partial Response (VGPR)
- ▲ Partial Response (PR)
- Stable Disease (SD)
- ➔ Ongoing treatment
- ✦ Progressive Disease (PD)
- ✖ Other

- 1 VGPR (ongoing)
- 3 PRs (1 ongoing)
- 2 SDs (both ongoing)
- 2 PD
- 3 withdrawn

PTX-100 dose


500 mg/m²

1000 mg/m²

2000 mg/m²

| | 121-012 PTCL | 121-016 PTCL* | 121-014 PTCL | 121-013 PTCL | 121-006 PTCL | 121-005 PTCL | 121-015 CTCL* | 121-011 CTCL* | 121-010 CTCL* | 121-002 CTCL | 121-003 PTCL |
|-----------------|--------------|---------------|--------------|--------------|--------------|--------------|---------------|---------------|---------------|--------------|--------------|
| *still on study | 1.0 | 1.9 | 1.3 | 1.8 | 2.5 | 2.8 | 3.8 | 4.8 | 6.5 | 13.6 | 32.1 |

Before



After




For personal use only

Before




After




ASX: PTX

For personal use only

Before



After



ASX: PTX

For personal use only

Before



After




ASX: PTX

Favourable safety profile compared to peers

Approved PTCL drugs have troublesome safety profiles

% Serious Adverse Events (≥Grade 3)
for Approved PTCL Drugs



PTX-100 HAS AN EXCELLENT SAFETY PROFILE

- No serious adverse events related to PTX-100
- Suits fragile patient population
- Good candidate for combination therapy

Now in Expansion Cohort for TCL

- 8 – 12 patients with r/r T cell lymphoma
- Expanding number for CTCL patients in light of responses
- Potential bridge to registration study
- Focussing on sweet spot in an area of considerable unmet need
- Shortest path to market

Case Study

- pralatrexate (Folotyn[®])
- Approved for PTCL
 - 5,600 cases/year in US
- US\$450,540 per patient, per year

FOLOTYN
(pralatrexate injection) 



ial use only


PTX-200

NOVEL AKT INHIBITION

Phase 1B trial underway: Acute Myeloid Leukemia

- Building upon encouraging Phase 1 results with PTX-200 (monotherapy)
- PI Professor Jeff Lancet at Moffitt, Key Opinion Leader in AML
- 24 patients with cytarabine held constant at 200-400 mg/m² as continuous infusion
 - 4 patients with CR/CRi so far
 - 1 patient with PR
- Currently treating expansion cohort at 45 mg/m²
- Granted Orphan Drug Designation by US FDA


Principal Investigator



Jeffrey E Lancet, M.D.





CR: COMPLETE REMISSION
CRi: COMPLETE RESPONSE WITH INCOMPLETE HEMATOLOGIC RECOVERY
PR: PARTIAL RESPONSE



CELL THERAPY PLATFORMS

The CAR-T process



1




Blood is collected from the patient

2

T-Cells are isolated

3

T-Cells are genetically altered to have cancer-recognising receptors (CARs)



4

Millions of CAR-T cells are grown

5

CAR-T cells are administered to the patient

CAR-T is booming

Immune cells shown to protect mice from cancer, origin of T cells discovered

1960

1990
T cell engineering begins; first-generation CARs developed; Antigen-specific T cells used in humans

2000
First effective CAR-T cells developed, CD19 successfully targeted

2000

2012
CAR-T licensed from Penn by Novartis to develop Kymriah®

2012

2017
FDA designates CARs a "break-through" therapy

2017

2023
GlobalData forecasts Kymriah® sales to exceed US\$1bn

2023

2028
GlobalData forecasts CAR-T sales to exceed US\$37bn

2028

2014
First CARs cross the regulatory finish line

2014

TODAY

- 10y+ remissions
- Continued positive data flow
- Some outstanding results
- 100s of companies targeting different antigens to target more cancer cells

Penn is a pioneer and world leader in CAR-T



original use only

- Novartis licensed CAR-T technology from Penn in 2012
- Kymriah® became the first CAR-T therapy approved by the FDA
- Used for certain blood cancers
- Cost of treatment in excess of \$500,000 per treatment
- GlobalData forecasts Kymriah® sales to exceed US\$1 billion in 2023



CAR-T's key challenges

Challenge



Safety / Control

No control post infusion



Targeting

Difficulties with targeting,
antigen heterogeneity



Escape

Difficulties with mutating antigens



Production efficiency

Cost prohibitive & slow



Exhaustion

Cells run out of steam



Trafficking

Cells cannot find their way



Tumor penetrance

Protective layer around tumor



Tumor microenvironment

Suppresses immune cells

Unsafe

Less effective

Not sustainable

Too expensive

Don't last

Platforms to overcome CAR-T's key challenges

Challenge






Safety / Control

No control post infusion



-



Targeting

Difficulties with targeting, antigen heterogeneity



-

Safe



Escape

Difficulties with mutating antigens



-

Effective



Production efficiency

Cost prohibitive & slow



-

Sustainable



Exhaustion

Cells run out of steam



Affordable



Trafficking

Cells cannot find their way



Enduring



Tumor penetrance

Protective layer around tumor



Tumor microenvironment

Suppresses immune cells




Internal use only



OmniCAR

**Universal, Next Gen
CAR-T Platform**

OmniCAR: flexible, modular CAR platform



Using any
targeting
ligand...

...with any
immune
cell



Associate Professor
Daniel J. Powell, Jr



Professor
Andrew Tsourkas



UNIVERSITY OF
OXFORD

mal use only

T-cell



OmniCAR can do what conventional CAR-T cannot

Conventional CAR-T



- Soldier with only one map
- Single weapon
- Only trained to hit one target
- Incapable of redirection
- No communication or control in the field



Armed with **any** weapon
Including **several** at once



OmniCAR



Can be given **any** map;
Multiple deployments



Full **communication**
and **control** at all times,
even mid-mission



Can direct against
any target, including
simultaneous targets




Send **images** back to
base in real time

OmniCAR: Control Features


Modular and covalent architecture of OmniCAR enables true **post-infusion control** of CAR functionality

Dose Titration




Control activity to **safe and efficacious** levels

On/off switch




Turn therapy on/off/on without killing or re-administering cells = **safety & persistence**

Target Re-direction




Re-direct cells from one cancer target to another in vivo

Multi-Antigen Targeting




Target **multiple cancer antigens simultaneously** for thorough cancer killing

Control: Dose-dependent CAR-T activity



- Ovarian cancer model, using anti-HER2 OmniCAR
- Loading more binder results in **proportionate killing** of cancer...
- ...and **proportionate survival**
- **Lasting effects** even when cease dosing of binder



OmniCAR cells can be Re-Armed





Wash; Rest

Re-armed

Cytotoxicity assay

Day 12


Days 13–14



- OmniCAR T cells can be re-armed
- Re-arming results in **same levels and kinetics of cytotoxicity** as pre-armed
- Another example of **flexible yet predictable** activity

OmniCAR cell can be Redirected

Target Re-direction in Coculture of GBM Cells expressing HER2 or EGFRviii



100nM EGFRviii OmniCAR cells added

100nM HER2LT added

1

OmniCAR T cells pre-armed with EGFRviii binder

→ Rapid cytotoxicity to EGFRviii+ cells

2

Add Her2 binder


→ Rapid switching & cytotoxicity to Her2+ cells

No new cells required

OmniCAR cells viable & armable for weeks

Mice with OC25 tumours


Binder administered from day 21



- Unarmed & armed OmniCAR-T cells are viable for weeks
- Can be armed at will
- Results in immediate cytotoxicity

Regulatory, manufacturing & COGS advantages

Conventional CAR-T



6 INDs

6 Manufacturing runs


6 Vectors/Transductions

6 Sets of release testing

No Flexibility

= 6 X (\$\$\$\$)

OmniCAR



1 IND

1 Optimized Manufacture

1 Vector/Transduction

1 Release program

Multiple binders off the shelf

No time delay for
subsequent doses

= (1 X \$\$\$) + (6 X \$)



OmniCAR

Next Gen CAR-T Programs

OmniCAR internal program summary

| Targets | Indications | OmniCAR features | Comments |
|------------------------|-----------------------------------|---|---|
| CD33 + CLL-1 | Acute Myeloid Leukemia (AML) | <ul style="list-style-type: none"> • Titration for improved safety • Co-arming against CD33 & CLL-1 • Sequential targeting | <ul style="list-style-type: none"> • Validated targets; expressed on 90%+ of AML blasts & LSCs • 1 of 5 programs worldwide; the only next-gen program |
| HER2 | Ovarian; breast & gastric cancers | <ul style="list-style-type: none"> • Titration for improved safety • Persistent binder dosing for improved efficacy • TME and checkpoint enhancements | <ul style="list-style-type: none"> • Most mature next-gen HER2 CAR-T program • Builds on Penn pre-clinical PoC |
| HER2 + EGFRviii | Glioblastoma multiforme (GBM) | <ul style="list-style-type: none"> • Titration for improved safety • Co-arming against HER2 & EGFRviii • Persistent binder dosing for improved efficacy | <ul style="list-style-type: none"> • 1 of 3 multiple antigen programs in the world • Single antigen targeting is inadequate in GBM |

OmniCAR progressing towards clinic

- Steady progress across all programs
- OmniCAR AML likely the first program in clinical trials
- Q-Gen Cell Therapeutics appointed as cell manufacturer
 - Clinical grade cells
 - Autologous T cells expressing SpyCatcher
 - Incorporating CellPryme-M for superior phenotype
- Prescient to articulate regulatory path and clinical development details shortly



MD Anderson Cancer Center



THE UNIVERSITY OF TEXAS
~~MD Anderson~~
Cancer Center
Making Cancer History®



MD Anderson's ECLIPSE platform has yielded novel TCR-like binders




MD Anderson's novel TCR-like binder library

- Broad library of samples from leukemia patients (ECLIPSE platform)
- Uncovered unique TCR-like binders
- Targets blood cancer cells differently to CAR-T

Strategic Collaboration

- Strategic collaboration to add novel TCR binder to OmniCAR
- Create best-in-class adaptable CAR-Ts for blood cancers
- Shared costs and outcomes

Adding TCR-like binder to OmniCAR for AML



- Using “plug & play” features of OmniCAR to combine novel TCR-like binder with CD33 & CLL-1 for AML
- Create an unprecedented level of multivalency and control.
- **For the first time**, we will be able to test:
 - Multivalent T cells that **have both CAR and TCR** targeting ligands using the **single internal cytotoxic machinery**
 - Has the potential to **make OmniCAR-T cells >1000x more sensitive** to rare or low abundance antigens
 - The impact of periodic resting on TCR-directed killing


Internal use only



CellPryme

**CELL THERAPY
ENHANCEMENTS**


The CAR-T process





1 Blood is collected from the patient



2 T-Cells are isolated



3 T-Cells are genetically altered to have cancer-recognising receptors (CARs)



4 Millions of CAR-T cells are grown



5 CAR-T cells are administered to the patient



CellPryme-M

MANUFACTURING ENHANCEMENT

- Produces longer lasting, more “youthful” CAR-T cells
- Doubles helper T cells
- Doubles tumour control
- More chemokine receptors for locating tumours



CellPryme-A

ADJUVANT THERAPY


- Overcomes hostile TME
- Reduces Tregs
- Increases expansion of CAR-T cells *in vivo*
- Doubles penetration of CAR-T cells into tumours

CellPryme Complements OmniCAR



OmniCAR

- Multi-targeting
- Redirection
- Control & safety
- Any target; any cell




Next generation
Cell therapies



CellPryme-M

Process that produces
a better cell type

- Persistence
- Trafficking



Current generation cell
therapies



CellPryme-A



Adjuvant therapy

- Reduces Tregs
- Primes TME for cell therapy
- Boosts CAR-T cell expansion *in vivo*



CellPryme-M

Cell manufacturing
enhancement

CellPryme-M Executive Summary



PROCESS TO ENHANCE CELL THERAPIES

- Incorporate into standard manufacturing
- Current gen and next gen
- Complementary to OmniCAR



PRODUCES SUPERIOR CELLS

- More “youthful” T cells
- More effective tumour killing
- Longer lasting



READY FOR CLINICAL TESTING



CellPryme-M IP FULLY OWNED BY PTX

Developed by PTX
in collaboration with Peter Mac

CellPryme-M produces CAR-T cell types with ideal characteristics and attributes



Persistence

For longevity of effects and continued tumour control



Immune memory

Central memory T cells typically persist 10-20 years and as long as 75 years



Trafficking

CAR-T cells able to find their way to the tumour



Tumour penetrance

Cells that can penetrate solid tumours



Genomic stability

Cells with enhanced self-renewal due to greater genomic stability




Anti-viral

Cells with potent anti-viral characteristics




More memory cells required for clinical efficacy

- Clinical efficacy of CAR-T therapy remains dependent on the T cell phenotype
- It is possible to control this during the manufacturing step




Greater Persistence: 50% more central memory cells than conventional CAR-T

CellPryme-M increases central memory T cells 1.5-fold within 24hrs




CellPryme-M doubles tumour control and survival


CellPryme-M nearly doubles CAR-T tumour control



CellPryme-M doubles survival



Greater Persistence/Less Exhaustion





Sustained increase in T^{CM}


for both cytotoxic CD8+ and helper CD4+

Sustained decrease in T^{EM}


for both cytotoxic CD8+ and helper CD4+



Synergy: CellPrime-M doubles proportion of helper T cells




- Shift towards dominant helper CD4+ CAR T cells
- Helper T cells are known to prevent the exhaustion of cytotoxic CD8+ T cells
 - Some can also have tumour killing ability
- Helper & cytotoxic T cells work in synergy to increase CAR-T persistence



Trafficking: greater chemokine receptor expression

- Effector T cells can downregulate chemokine receptors (CXCR3), limiting the ability of conventional CAR-T cells to locate tumours
- CellPryme-M significantly increases CXCR3 expression on CAR-T cells
- Better trafficking to tumour site
- Better tumour penetrance

Chemokine receptor expression on CD8+ cytotoxic CAR-T cells





CellPryme-A

**Adjuvant for enhancing
cell therapies**

CellPryme-A Summary

ADJUVANT PLATFORM TO ENHANCE CELL THERAPIES

- Current gen and next gen
- Complementary to CellPryme-M & OmniCAR

BREAKS DOWN HOSTILE TME

- Two-thirds less intratumoral Tregs
- Increases CAR-T cell penetration into tumours

IMPROVES TUMOUR KILLING AND SURVIVAL

READY FOR CLINICAL TESTING

- GMP material ready


BOOSTS CAR-T EXPANSION *IN VIVO*

DEVELOPMENT OPPORTUNITIES

- PTX & 3rd party programs
- Use with any existing cell therapy for solid tumours

CellPryme-A addresses the hostile Tumour Microenvironment (TME)

- TME is the **complex ecosystem** surrounding solid tumours
- Protects and nurtures the cancer
- Acts as a **protective “force field”** that blunts the effectiveness of cancer therapies




Treg cells are central players in the TME

Tregs are immunosuppressive cells in the TME

(i.e. suppresses the immune response)

- Causes T cell **exhaustion**
- Causes T cell **death**
- Produces cytokines that cause the tumour to go “**cold**”
- **Impairs NK** cell function

Reducing Tregs is key to
successful CAR-T therapy



Summary of CellPryme-A effects




Boosts tumour killing by conventional CAR-T cells



Improved survival



Reduces problematic **Treg cells** by 66%



Dramatically increases **CAR-T cell expansion** within

- 2x ↑ CAR-T cell expansion
 - 9x ↑ Cytotoxic T cells
 - 6x ↑ Helper T cells
- host] with CellPryme-M




Increases ability of T cells to **penetrate solid tumours**

- 4x ↑ Cytotoxic T cells
- 3x ↑ Helper T cells




Synergises with CellPryme-M for **even greater benefits**

CellPryme-A significantly boosts CAR-T efficacy



Experimental end point
 Tumour size > 150 mm² or ≤ 28 days unless other humane endpoints are reached


- Untreated
- CAR-T cells
- CAR T cells + **CellPryme-A**
- CellPryme-M CAR-T cells + **CellPryme-A**




Untreated




CAR-T cells alone



CellPryme-A + CAR-T cells




CellPryme-A + CellPryme-M CAR-T cells




CellPryme-A improves survival

- Highly aggressive and resistant cancer model
- CAR-T cells did not improve survival in this model
- CellPryme-A improved the survival of animals given CAR-T cells by over 20% (5 days)
- The combination of CellPryme-A and CellPryme-M treated CAR-T cells **extended survival beyond the study period** in half of the animals under experimentation

□ Note: Animal ethics approval up to 150mm² or up to 28 days on study unless other humane endpoints are reached



CellPryme-A significantly decreases problematic Tregs in tumours




CellPryme-A significantly reduced intra-tumoural Tregs by two-thirds


Conventional Her2 CAR-T cell therapy followed by CellPryme-A adjuvant therapy

* $p < 0.05$; Kruskal-Wallis one-way ANOVA

CellPryme-A synergises with CellPryme-M to dramatically expand CAR-T cells *in vivo*




↑9x




↑6x

CD8+ Cytotoxic T cells



CD4+ T helper cells

CellPryme-A significantly increases CAR-T cell penetration into tumours



p<0.01, **p<0.0001, Mann-Whitney test

Tumours collected from parallel cohort of animals at Day 21

CellPryme-A ready for the clinic



CLINIC-READY THERAPY


- Ready for clinical testing as adjuvant/neoadjuvant therapy
- Straightforward to incorporate adjuvant into other CAR-T programs
- Robust regulatory package
- Clinical grade material available

CAR-T cells




 CellPryme-A






BUSINESS MODEL & SCOPE

Prescient's CAR-T platform business model



- Huge market
- “Shovels to CAR-T goldrush”
- Diversified risk
- Highly scalable
- Earlier revenue potential

Commercial models - Partners



Internal use only

The End Game: Personalized “Plug & Play” Cell Therapy Ecosystem

Step 4:

Bespoke therapy with
post-infusion control

Step 3:


Pair binders with OmniCAR cells
(T cells; NK; auto/allo)

Step 2:

Match patient's antigens
to corresponding binders

Step 1:

Patient sample to determine
individual antigen profile



Summary

Top-down analysis is sensible for investors


1



Oncology*

- 2021: US\$ 280bn
- 2029: US\$ 536bn (8.2% CAGR)


2



Cell Therapies (CAR-T)

- >US\$37bn by 2028[^]

3



Prescient Therapeutics

- Next gen platforms
- Scalable
- Controllable
- Any target; any cell
- “Shovels to goldrush” position
- Top pedigree



Investment Thesis Summary

4 blue chip oncology assets



2 next gen platforms



PTX-100 & PTX-200
in clinic



Top pedigree



OmniCAR PTX-100



CellPryme PTX-200

Superior positioning & model



Internal products
+ external partnering



Shovels to goldrush



Highly scalable



Huge & growing market



\$280bn industry



Growing demand



Cell therapy is the future





Thank you!

ASX code: PTX

www.ptxtherapeutics.com

Internal use only